RT Journal Article
T1 Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib.
A1 Hidalgo-Ríos, Samuel
A1 Carrillo-García, Jaime
A1 Moura, David S
A1 Stacchiotti, Silvia
A1 López-Pousa, Antonio
A1 Redondo, Andrés
A1 Italiano, Antoine
A1 Gutiérrez, Antonio
A1 Grignani, Giovanni
A1 Hindi, Nadia
A1 López-Guerrero, José-Antonio
A1 Muro, Xavier García Del
A1 Trufero, Javier Martínez
A1 Palmerini, Emanuela
A1 García, Ana Sebio
A1 Bernabeu, Daniel
A1 Le Cesne, Axel
A1 Casali, Paolo Giovanni
A1 Blay, Jean-Yves
A1 Cruz Jurado, Josefina
A1 Martin-Broto, Javier
K1 NLR
K1 PLR
K1 RDW
K1 inflammation
K1 neutrophil/lymphocyte ratio
K1 pazopanib
K1 platelet/lymphocyte
K1 red cell distribution width
K1 solitary fibrous tumour
AB Pazopanib was assessed prospectively in the GEIS-32 phase II study (NCT02066285) on advanced solitary fibrous tumour (SFT), resulting in a longer progression-free survival (PFS) and overall survival (OS) compared with historical controls treated with chemotherapy. A retrospective analysis of peripheral inflammatory indexes in patients enrolled into GEIS-32 was performed to evaluate their prognostic and predictive value. Patients received pazopanib 800 mg/day as the first antiangiogenic line. The impacts of baseline neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and red cell distribution width (RDW) on PFS, OS, and Choi response were evaluated by univariate and multivariate analysis. Metastasis-free interval (MFI), mitotic count, and ECOG were also included as potential prognostic factors. Sixty-seven SFT patients, enrolled in this study, showed a median age of 63 years and a female/male distribution of 57/43. The median follow-up from treatment initiation was 16.8 months. High baseline NLR, PLR, and standardised RDW were significantly associated with worse PFS and OS. NLR, RDW, MFI, and mitotic count were independent variables for PFS, while RDW and ECOG were independent for OS. Further, NLR and mitotic count were independent factors for Choi response. High baseline NLR and RDW values were independent prognostic biomarkers for worse outcome in advanced SFT patients treated with pazopanib.
SN 2072-6694
YR 2022
FD 2022-08-29
LK http://hdl.handle.net/10668/20915
UL http://hdl.handle.net/10668/20915
LA en
DS RISalud
RD Apr 5, 2025